Ivan A. T.
- Country
- Spain
- Department
- Instituto de Mastocitosis de Castilla La Mancha
Research Overview
- (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis
- Evaluation of TL-895 in Myelofibrosis, Indolent Systemic Mastocytosis, and Mast Cell Activation Syndrome: A Phase 2 Multicenter Study
- Evaluation of BLU-263 Monotherapy and BLU-263 Combined with Azacitidine in Patients with KIT-Altered Advanced Systemic Mastocytosis
Data & Insights
Has run more than one trial at 31 of 79 partner sites.
Specializations
Advanced Mastocytosis Research
The investigator specializes in treating advanced systemic mastocytosis (AdvSM) and explores innovative therapeutic approaches for patients with KIT-altered hematologic malignancies. Their research encompasses both monotherapy and combination treatment strategies.
- Advanced systemic mastocytosis management
- KIT mutation targeted therapies
- Combination therapy approaches
Non-Advanced Mastocytosis Studies
The investigator focuses on treating indolent systemic mastocytosis (ISM) and smoldering systemic mastocytosis. Their work includes evaluation of novel therapeutic agents for symptom management and disease control in non-advanced forms of the condition.
- Symptom assessment and management
- Long-term disease monitoring
- Quality of life improvements
Related Hematologic Conditions
The investigator's expertise extends to related conditions including myelofibrosis and mast cell activation syndrome (MCAS). Their research encompasses both monoclonal and non-monoclonal variants of these disorders.
- Myelofibrosis treatment approaches
- Mast cell disorders
- Systemic disease management
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.